<a target="_blank" href="https://www.buzzsprout.com/twilio/text_messages/2342317/open_sms">Send us a text</a>In recent years we have seen a marked change in the landscape of treatment for endometrial cancer. This has been driven by understanding the different molecular subtypes of endometrial cancer. POLE - with an excellent prognosis MMR deficient - with good prognosis and option for immunotherapy No Specific molecular profile - intermediate outcome and work still to be done P53 mutant - with a poorer outcome Dr Angela George from the Royal Marsden Hospital has a specialist interest in genomics and shares her expertise and knowledge on this fascinating area of gynaecological cancers.

Welcome to Simply Oncology.&nbsp;Cancer is daunting for both patients and for clinical teams.Dr John McGrane and Dr Michael Rowe are oncologists who want to break down the complex parts of cancer care into clear and simple sessions.We will dive deep into the world of cancer research, patient stories and the latest cancer breakthroughs.&nbsp;Simply Oncology will have patient focused episodes along with episodes that allow anyone with an interest in oncology to stay up to date.We hope you join us as we unpick all parts of cancer.&nbsp;John &amp; Mike